[1] PALUMBO A,ANDERSON K.Multiple myeloma[J].N Engl J Med,2011,364(11):1046-1060.
[2] RAJKUMAR S V,DIMOPOULOS M A,PALUMBO A,et al.International myeloma working Group updated criteria for the diagnosis of multiple myeloma[J].Lancet Oncol,2014,15(12):e538-e548.
[3] RAJKUMAR S V.Multiple myeloma:2014 update on diagnosis risk-stratification,and management[J].Am J Hematol,2014,89(10):999-1009.
[4] LANDGREN O,GRIDLEY G,TURESSON I,et al.Risk of monoclonal gammopathy of undetermined significance(MGUS) and subsequent multiple myeloma among African American and white veterans in the United States[J].Blood,2006,107(3):904-906.
[5] SHORT K D,RAJKUMAR S V,LARSON D,et al.Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy,and the activity of pomalidomide on extramedullary myeloma[J].Leukemia,2011,25(6):906-908.
[6] 陈海飞,傅卫军,王东星,等.40例多发性骨髓瘤伴髓外病变患者的临床特征分析[J].中华血液学杂志,2007,28(10):655-658.
[7] BERGSAGEL P L,KUEHL W M.Chromosome translocations in multiple myeloma[J].Oncogene,2001,20(40):5611-5622.
[8] FONSECA R,BAILEY R J,AHMANN G J,et al.Genomic abnormalities in monoclonal gammopathy of undetermined significance[J].Blood,2002,100(4):1417-1424.
[9] SEIDL S,KAUFMANN H,DRACH J.New insights into the pathophysiology of multiple myeloma[J].Lancet Oncol,2003,4(9):557-564.
[10] RAJAN A M,RAJKUMAR S V.Interpretation of cytogenetic results in multiple myeloma for clinical practice[J].Blood Cancer J,2015,5(10):e365. |